

## A Study on Glucose Tolerance Test at Different Stages

R. Salma Mahaboob<sup>1</sup>, G. Anitha<sup>2\*</sup>

<sup>1</sup>Assistant professor in Biochemistry at Fathima Institute of Medical Sciences, Kadapa, Andhra Pradesh, India

<sup>2</sup>Professor of Biochemistry at Fathima Institute of Medical Sciences, Kadapa, Andhra Pradesh, India

\*Corresponding author: Dr. G. Anitha

| Received: 20.03.2019 | Accepted: 28.03.2019 | Published: 31.03.2019

DOI: [10.36348/sijb.2019.v02i03.003](https://doi.org/10.36348/sijb.2019.v02i03.003)

### Abstract

The glucose tolerance signifies the ability of the body to dispose off an additional load of glucose given. This test is useful in distinguishing a person with a normal glucose tolerance from people who have increased tolerance in disease conditions. Aim of the study to study on glucose tolerance test. Approximately 40% of subjects who will develop type 2 diabetes are within the NGT range at OGTT, indicating that there is a large number of NGT subjects who constitute the larger reservoir of future type 2 diabetes. OGTT detects diabetes more efficiently than FPG as it recognizes altered post-prandial metabolism.

**Keywords:** glucose tolerance, diabetes, NGT, OGTT.

**Copyright © 2019:** This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (Non-Commercial, or CC-BY-NC) provided the original author and source are credited.

### INTRODUCTION

In the world the prevalence of type 2 diabetes is increasing at an disturbing rate. The number of people with type 2 diabetes globally is projected to increase from 171 million in 2000 to 366 million by the year of 2030 [1]. This increase, closely linked to the upsurge of obesity, represents a global health care problem for the related micro- and macro-vascular complications [2].

The glucose tolerance signifies the ability of the body to dispose off an additional load of glucose given. This test is useful in distinguishing a person with a normal glucose tolerance from people who have increased tolerance in disease conditions [3].

Each normal individual displays a characteristic time related blood glucose response following ingestion of a known amount of glucose. It essentially involves body's ability to absorb glucose and metabolize it by secreting adequate insulin. This response is altered many a time and indicates several abnormalities of carbohydrate metabolism [4].

### INDICATIONS

- In diagnosis of diabetes mellitus and impaired glucose tolerance in doubtful subjects.
- Evaluation of non – diabetic glycosuria.
- Confirmation of gestational diabetes [5].


### PRE – REQUISITES:

- The patient should be on a normal unrestricted diet containing at least 150g of carbohydrate for 3 days.
- Test should preferably be performed after an overnight fast in the morning on an empty stomach. In case of emergency it can be done after 4 -5 hrs of last meal. A weak tea without sugar and milk can be allowed.
- The patient should be relaxed, seated and not involved in physical activity. There should be no smoking before and during the test.
- All medicines affecting carbohydrate metabolism should be stopped e.g. insulin and other anti diabetic drugs, steroids, oral contraceptives etc [6].

### PROCEDURE

GTT can be performed in two ways depending upon the route of glucose load administration i.e. oral GTT and intravenous GTT.

After an overnight fast (12-14 hrs after the last meal) the subject is ready for the test. In the early morning fasting blood and urine samples are collected. The subject is administered an oral dose of glucose, normally 75gm glucose dissolved in about 200ml water and flavoured, is given. The time is noted. At intervals of 60 and 120 minutes blood samples are withdrawn and urine specimens are collected. Blood glucose levels are determined quantitatively in samples. Sugar in urine specimens is tested quantitatively. The blood glucose values are plotted on a graph sheet as a function of time [7].




**Fig-1: Shows types of oral glucose tolerance test**

**Normal response**

The fasting blood glucose levels will be in the range of 60-100mg% .30 -60 minutes after glucose administration the blood sugar levels rises peak value of 100 – 130 mg%. The peak value does not exceed the renal threshold level of 180 mg% and there will be no glucose in the urine samples. The initial rise is observed because the quantity of glucose absorbed from the

intestine exceeds the capacity of liver and other tissues to use it. Increased glucose levels in blood stimulates insulin secretion which facilitates the enhanced utilization of glucose by the peripheral tissue. As a results the blood glucose levels starts declining and may dip to a value slightly lower than the fasting levels at the end of 2 hrs [8-10].




**Graph-1: Shows normal glucose curve**

**DECREASED TOLERANCE**

Decreased tolerance is found in diabetes mellitus. Fasting blood sugar values above 126 mg % and 2 hrs value above 200mg% are characteristic of

diabetic mellitus. Diminished glucose tolerance is also observed in hyperthyroidism, in hyper activity of adrenals and in severe liver disease [11, 12].




Graph-2: Shows Glucose tolerance test in diabetes

### INCREASED TOLERANCE

The graph will appear flatter than a normal response curve. Even in some normals such a profile is found. Increased tolerance is observed in hyperthyroidism, hypoadrenalism and hypopituitarism [13]. Increased tolerance can also be observed in patients with intestinal disorders like idiopathic

steatorrhea, sprue and coeliac disease, the abnormal response in these latter cases reflects an impaired absorption of glucose. In such conditions the intravenous glucose tolerance test is performed to assess the ability of the body to dispose off an additional glucose load [14, 15].



Graph-3: Shows oral glucose tolerance test

## REFERENCES

1. Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes care*, 27(5), 1047-1053.
2. Hossain, P. (2007). Kaw ar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. *N. Engl. J. Med*, 356, 213-5.
3. Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., ... & Salminen, V. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine*, 344(18), 1343-1350.
4. Hedderson, M. M., Ferrara, A., & Sacks, D. A. (2003). Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. *Obstetrics & Gynecology*, 102(4), 850-856.
5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *The Lancet*, 368(9541), 1096-1105.
6. Naylor, C. D., Sermer, M., Chen, E., & Sykora, K. (1996). Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style?. *Jama*, 275(15), 1165-1170.
7. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *The New England journal of medicine*, 346(6), 393-403.
8. American Diabetes Association. (2006). Diabetes Care. Standards of Medical Care-Table 6 and Table 7, Correlation between A1C level and Mean Plasma Glucose Levels on Multiple Testing over 2-3 months. 29(1), 51-58.
9. Crowther, C. A. (2005). Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med*, 352, 2477-2486.
10. Lu, Z. X., Walker, K. Z., O'dea, K., Sikaris, K. A., & Shaw, J. E. (2010). A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. *Diabetes care*, 33(4), 817-819.
11. ACOG Practice Bulletin. (2001). Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. *Obstet Gynecol*, 98(3), 525-538.
12. Monnier, L., Lapinski, H., & Colette, C. (2003). Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. *Diabetes care*, 26(3), 881-885.
13. Phillips, L. S., Weintraub, W. S., Ziemer, D. C., Kolm, P., Foster, J. K., Vaccarino, V., ... & Caudle, J. M. (2006). All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1). *Diabetes Care*, 29(6), 1405-1407.
14. Unwin, N., Shaw, J., & Zimmet, P., Alberti, K. (2002). Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med*; 19:708-723.
15. Gerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., ... & Booker, L. (2007). Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. *Diabetes research and clinical practice*, 78(3), 305-312.